UCB
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases.
RELATED ARTICLES
Researcher Profile: Eddy Han-Burgess
Eddy Han-Burgess and his team are using a mix of mathematical modeling, big data and artificial inte…
READ MORE
Researcher Profile: Henrik Klitgaard
With nearly 30 years of experience in biopharmaceutical research, Dr. Henrik Klitgaard has dedicated…
READ MORE
Taking Control of Epilepsy
As the most common serious neurological condition in the U.S., epilepsy affects roughly 3.4 million…
READ MORE
Pursuing Novel and Targeted Treatments for Epilepsy
Epilepsy is a complex condition, and it will take an equally complex approach to put an end to the d…
READ MORE
Researcher Profile: Luiz Miguel Camargo
As director of innovation networks at UCB, Dr. Luiz Miguel Camargo helps identify tools that researc…
READ MORE
Researcher Profile: Victor Sloan
As vice president and development strategy lead at UCB, Victor Sloan has worked in the field of rheu…
READ MORE
Tackling Epilepsy to Deliver Value to Patients
Brain diseases affect one in six people around the world. The range of conditions affecting the cent…
READ MOREPOPULAR ARTICLES
Can We Afford the New Era of Medicine?
Innovative treatments require innovative partnerships. America's Biopharmaceutical Companies and insurers are partnering to get the right medicine in the hands of patients who need them.
READ MORE
Researcher Profile: Jirong Lu
Dr. Jirong Lu, a distinguished research fellow at Eli Lilly and Company (Lilly), traces the beginnings of her career to a high school fascination with chemistry.
READ MORE
We Cannot Take Progress for Granted
We are in a new era of medical discovery and have the potential to revolutionize the treatment of costly and debilitating diseases. But we must not take this progress for granted.
READ MORE
The Greatest Gift of All: Hope
My son Parker's journey with juvenile arthritis (JA) began 10 years ago when he was in elementary school.
READ MORE
Migraine: More than Just a Bad Headache
Migraine is a debilitating neurological disease that is often misunderstood by those who do not suffer symptoms, according to the Migraine Impact Report, a new survey recently released by Eli Lilly and Company and conducted by Nielsen.
READ MORE
Washington is considering policy changes that could threaten innovation
New policy proposals in Washington threaten to hamstring investment in innovation and jeopardize breakthroughs.
READ MORE
Tackling Neurological Disorders in New Ways
Chronic pain. Alzheimer's disease. Multiple Sclerosis. Brain tumors. These are some of the most well-known and prevalent diseases afflicting the more than 100 million Americans who are impacted by a neurological disorder.
READ MORE